Welcome to our dedicated page for Grail news (Ticker: GRAL), a resource for investors and traders seeking the latest updates and insights on Grail stock.
GRAIL reports news on its healthcare business focused on early cancer detection through the Galleri multi-cancer early detection blood test. The company uses next-generation sequencing, population-scale clinical studies, machine learning, software and automation within a targeted methylation-based platform designed to detect and identify multiple cancer types in earlier stages.
Recurring updates include Galleri revenue and test-volume trends, clinical data from programs such as NHS-Galleri and PATHFINDER 2, regulatory and evidence-generation activity, health-system access initiatives, commercial partnerships, conference presentations, equity incentive grants and governance changes. Company announcements also describe how its platform may support screening and precision oncology uses, including risk stratification, minimal residual disease detection, biomarker subtyping, treatment monitoring and recurrence monitoring.
GRAIL (Nasdaq: GRAL) reported Q1 2026 results on May 5, 2026. Total revenue rose 28% year-over-year to $40.8 million and Galleri revenue grew 37% to $39.8 million. Galleri test volume increased 50% to more than 56,000 tests. Net loss was $93.2 million; cash and short-term investments were $823.1 million. The FDA accepted the PMA for review and Epic EHR integration is planned for broad availability by end of 2026. New NHS-Galleri and PATHFINDER 2 data will be presented at ASCO 2026.
GRAIL (Nasdaq: GRAL) will present at the BofA Securities 2026 Health Care Conference in Las Vegas on Tuesday, May 12, 2026 at 8:40 a.m. PT. Live and replay webcasts will be available via the investor relations site and archived for at least 30 days.
GRAIL (Nasdaq: GRAL) will issue first quarter 2026 financial results after market close on Tuesday, May 5, 2026. Management will host a webcast and conference call at 1:30 p.m. PT / 4:30 p.m. ET to discuss results and business progress.
A live webcast and recorded replay will be available at the investor relations site, and registration is requested for the teleconference and webcast to ensure timely connection.
GRAIL (Nasdaq: GRAL) will present late-breaking NHS-Galleri and PATHFINDER 2 results at the 2026 ASCO Annual Meeting, May 29–June 2 in Chicago.
The NHS-Galleri randomized trial screened >142,000 participants; PATHFINDER 2 includes >32,000 evaluable participants, >174,000 combined, with oral presentations on May 30–31, 2026.
GRAIL (Nasdaq: GRAL) announced on April 7, 2026 a collaboration with Epic to integrate the Galleri multi-cancer early detection test into the Epic EHR via Epic Aura. The integration aims to enable ordering, results delivery, and follow-up within existing clinician workflows for approximately 450 health systems, with implementation planning begun in Q1 2026 and broad availability expected by the end of 2026.
Superpower (partnering with GRAIL, Nasdaq: GRAL) announced a strategic partnership on April 1, 2026 to offer the Galleri multi-cancer early detection test through Superpower's preventative health platform.
Galleri detects signals from more than 50 cancer types, PATHFINDER 2 showed detection rose more than seven-fold, and over half of cancers found were stage I or II. Testing is available via Quest's ~3,000+ patient access points, requires a prescription, and is recommended for adults at elevated risk (eg, aged 50+).
GRAIL (Nasdaq: GRAL) announced that CEO Bob Ragusa will retire effective June 1, 2026, and that President Josh Ofman, MD, MSHS, will succeed him and join the Board immediately. Ragusa will remain on the Board until June 1, 2026, and serve as a senior advisor through March 2027.
The Board described Ofman's background in clinical medicine, health policy, reimbursement, and leadership of the Galleri evidence program as key to continuity and advancing regulatory and commercial progress.
GRAIL (Nasdaq: GRAL) granted inducement equity awards of restricted stock units covering an aggregate of 19,500 shares to 20 newly hired non-executive employees under its Inducement Equity Incentive Plan dated March 2, 2026.
The RSUs vest over approximately four years, with 25% vesting Feb. 28, 2027 and the remainder vesting on each annual anniversary thereafter, subject to continued employment.
GRAIL (Nasdaq: GRAL) said company management will present at the TD Cowen 46th Annual Health Care Conference in Boston on Mar. 3, 2026 at 10:30 a.m. ET.
Live and replay webcasts will be available via the company's investor relations website and archived for at least 30 days after the event.
GRAIL (Nasdaq: GRAL) reported Q4 2025 revenue of $43.6M (14% YoY) and full‑year revenue of $147.2M (17% YoY). U.S. Galleri revenue was $136.8M (26% YoY). Net loss was $99.2M for Q4 and $408.4M for 2025.
The company completed its PMA submission to FDA, reported NHS‑Galleri topline results (reduced Stage IV but did not meet primary endpoint), finished PATHFINDER 2 analysis, and held $904.4M cash, providing runway into 2030.